Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) traded up 1.2% on Wednesday . The company traded as high as $12.00 and last traded at $12.00. 2,105 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 26,622 shares. The stock had previously closed at $11.86.
Finch Therapeutics Group Stock Up 1.2 %
The firm’s 50-day simple moving average is $11.69 and its 200 day simple moving average is $7.18.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
See Also
- Five stocks we like better than Finch Therapeutics Group
- Dividend Capture Strategy: What You Need to Know
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- How to Invest in the FAANG Stocks
- 3 Penny Stocks Ready to Break Out in 2025
- Find and Profitably Trade Stocks at 52-Week Lows
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
